Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

1997-12-11

Original market date: See footnote 1

1983-12-31

Product name:

HUMULIN N

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

00587737

Product Monograph/Veterinary Labelling:

Date: 2021-03-26 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

ELI LILLY CANADA INC
SUITE 900 Exchange Tower, 130 King Street West
Toronto
Ontario
Canada M5X 1B1

Class:

Human

Dosage form(s):

Suspension

Route(s) of administration:

Subcutaneous

Number of active ingredient(s):

1

Schedule(s):

Schedule D

 

American Hospital Formulary Service (AHFS): See footnote 3

68:20.08 

Anatomical Therapeutic Chemical (ATC): See footnote 4

A10AC01 INSULIN (HUMAN)

Active ingredient group (AIG) number:See footnote5

0115861001

List of active ingredient(s)
Active ingredient(s) Strength
INSULIN NPH HUMAN DNA ORIGIN 100 UNIT / ML

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Version 4.0.2
Date modified: